vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Fat Brands, Inc (FAT). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $140.0M, roughly 1.4× Fat Brands, Inc). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs -2.3%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs -6.1%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
FAT Brands Inc. is an American multi-brand restaurant and sports bar franchise operator headquartered in Beverly Hills, California.
AXSM vs FAT — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $140.0M |
| Net Profit | — | $-58.2M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | -12.4% |
| Net Margin | — | -41.6% |
| Revenue YoY | 57.4% | -2.3% |
| Net Profit YoY | — | -30.1% |
| EPS (diluted) | — | $-3.39 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | — | ||
| Q3 25 | $171.0M | $140.0M | ||
| Q2 25 | $150.0M | $146.8M | ||
| Q1 25 | $121.5M | $142.0M | ||
| Q4 24 | $118.8M | $145.3M | ||
| Q3 24 | $104.8M | $143.4M | ||
| Q2 24 | $87.2M | $152.0M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | — | ||
| Q3 25 | $-47.2M | $-58.2M | ||
| Q2 25 | $-48.0M | $-54.2M | ||
| Q1 25 | $-59.4M | $-46.0M | ||
| Q4 24 | $-74.9M | $-67.4M | ||
| Q3 24 | $-64.6M | $-44.8M | ||
| Q2 24 | $-79.3M | $-39.4M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | — | ||
| Q3 25 | -27.0% | -12.4% | ||
| Q2 25 | -24.5% | -10.6% | ||
| Q1 25 | -46.9% | -6.0% | ||
| Q4 24 | -61.1% | -27.1% | ||
| Q3 24 | -59.8% | -6.2% | ||
| Q2 24 | -89.5% | -1.8% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | — | ||
| Q3 25 | -27.6% | -41.6% | ||
| Q2 25 | -32.0% | -36.9% | ||
| Q1 25 | -48.9% | -32.4% | ||
| Q4 24 | -63.1% | -46.4% | ||
| Q3 24 | -61.7% | -31.2% | ||
| Q2 24 | -91.0% | -25.9% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | — | ||
| Q3 25 | $-0.94 | $-3.39 | ||
| Q2 25 | $-0.97 | $-3.17 | ||
| Q1 25 | $-1.22 | $-2.73 | ||
| Q4 24 | $-1.54 | $-4.06 | ||
| Q3 24 | $-1.34 | $-2.74 | ||
| Q2 24 | $-1.67 | $-2.43 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | — |
| Total DebtLower is stronger | $70.0M | $1.3B |
| Stockholders' EquityBook value | — | $-585.8M |
| Total Assets | $713.6M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | — | ||
| Q3 25 | $325.3M | — | ||
| Q2 25 | $303.0M | — | ||
| Q1 25 | $300.9M | — | ||
| Q4 24 | $315.4M | — | ||
| Q3 24 | $327.3M | — | ||
| Q2 24 | $315.7M | — |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.2B | ||
| Q2 24 | — | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | — | ||
| Q3 25 | $73.7M | $-585.8M | ||
| Q2 25 | $73.1M | $-536.5M | ||
| Q1 25 | $53.2M | $-493.9M | ||
| Q4 24 | $57.0M | $-455.7M | ||
| Q3 24 | $92.9M | $-386.1M | ||
| Q2 24 | $102.9M | $-338.6M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | — | ||
| Q3 25 | $669.3M | $1.2B | ||
| Q2 25 | $639.8M | $1.2B | ||
| Q1 25 | $596.7M | $1.3B | ||
| Q4 24 | $568.5M | $1.3B | ||
| Q3 24 | $561.5M | $1.3B | ||
| Q2 24 | $548.2M | $1.4B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-14.5M |
| Free Cash FlowOCF − Capex | — | $-16.9M |
| FCF MarginFCF / Revenue | — | -12.1% |
| Capex IntensityCapex / Revenue | — | 1.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-75.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $1.0M | $-14.5M | ||
| Q2 25 | $-32.4M | $-26.9M | ||
| Q1 25 | $-43.4M | $-13.2M | ||
| Q4 24 | $-26.2M | $-10.4M | ||
| Q3 24 | $-18.6M | $-3.2M | ||
| Q2 24 | $-30.1M | $-14.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | — | ||
| Q3 25 | $988.0K | $-16.9M | ||
| Q2 25 | $-32.4M | $-29.3M | ||
| Q1 25 | $-43.7M | $-17.8M | ||
| Q4 24 | $-26.2M | $-11.0M | ||
| Q3 24 | $-18.7M | $-11.1M | ||
| Q2 24 | $-30.2M | $-24.4M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | — | ||
| Q3 25 | 0.6% | -12.1% | ||
| Q2 25 | -21.6% | -20.0% | ||
| Q1 25 | -36.0% | -12.5% | ||
| Q4 24 | -22.1% | -7.6% | ||
| Q3 24 | -17.9% | -7.7% | ||
| Q2 24 | -34.6% | -16.1% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.3% | 3.2% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.1% | 5.5% | ||
| Q2 24 | 0.1% | 6.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
FAT
| Restaurant Sales | $96.6M | 69% |
| Royalty | $21.6M | 15% |
| Factory | $9.6M | 7% |
| Advertising | $9.1M | 7% |
| Franchisor | $1.5M | 1% |
| Other | $1.5M | 1% |
